Equity
Total Equity
Alnylam Pharmaceuticals Total Equity increased by 36.3% to $1.08B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 152.4%, from $426.14M to $1.08B. Over 5 years (FY 2020 to FY 2025), Total Equity shows a downward trend with a -4.9% CAGR.
Analysis
StatementBalance Sheet Statement
SectionEquity
First reportedQ4 2012
Last reportedQ1 2026Apr 30, 2026
Metric ID:
total_stockholders_equityHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $853.36M | $755.89M | $588.20M | $401.17M | $176.04M | -$67.64M | -$158.22M | -$259.24M | -$408.13M | -$165.87M | -$220.64M | -$219.27M | -$3.07M | $32.35M | $67.09M | $426.14M | $250.59M | $233.89M | $789.18M | $1.08B |
| QoQ Change | — | -11.4% | -22.2% | -31.8% | -56.1% | -138.4% | -133.9% | -63.8% | -57.4% | +59.4% | -33.0% | +0.6% | +98.6% | >999% | +107.4% | +535.2% | -41.2% | -6.7% | +237.4% | +36.3% |
| YoY Change | — | — | — | — | -79.4% | -108.9% | -126.9% | -164.6% | -331.8% | -145.2% | -39.5% | +15.4% | +99.2% | +119.5% | +130.4% | +294.3% | >999% | +622.9% | >999% | +152.4% |
Range-$408.13M – $1.08B
CAGR+5.0%
Avg YoY Growth+611.5%
Median YoY Growth+57.3%
Current Streak2 quarters growth
Total Equity at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's total equity?
- Alnylam Pharmaceuticals (ALNY) reported total equity of $1.08B in Q1 2026.
- How has Alnylam Pharmaceuticals's total equity changed year-over-year?
- Alnylam Pharmaceuticals's total equity increased by 152.4% year-over-year, from $426.14M to $1.08B.
- What is the long-term trend for Alnylam Pharmaceuticals's total equity?
- Over 5 years (2020 to 2025), Alnylam Pharmaceuticals's total equity has grown at a -4.9% compound annual growth rate (CAGR), from $1.02B to $789.18M.